D
Zeo ScientifiX, Inc.
ZEOX
$2.70
$0.000.00%
D
Sell
9/16/2024Upgraded
Zeo ScientifiX, Inc. (ZEOX) was upgraded to D- from E+ on 9/16/2024 due to an increase in the volatility index and total return index.
Zeo ScientifiX, Inc. (ZEOX) was upgraded to D- from E+ on 9/16/2024 due to an increase in the volatility index and total return index.
E
Sell
8/30/2024Downgrade
Zeo ScientifiX, Inc. (ZEOX) was downgraded to E+ from D- on 8/30/2024 due to a decline in the volatility index.
Zeo ScientifiX, Inc. (ZEOX) was downgraded to E+ from D- on 8/30/2024 due to a decline in the volatility index.
D
Sell
8/15/2024Upgraded
Zeo ScientifiX, Inc. (ZEOX) was upgraded to D- from E+ on 8/15/2024 due to an increase in the volatility index, total return index and valuation index.
Zeo ScientifiX, Inc. (ZEOX) was upgraded to D- from E+ on 8/15/2024 due to an increase in the volatility index, total return index and valuation index.
E
Sell
7/25/2024Downgrade
Zeo ScientifiX, Inc. (ZEOX) was downgraded to E+ from D- on 7/25/2024 due to a decline in the volatility index, total return index and valuation index.
Zeo ScientifiX, Inc. (ZEOX) was downgraded to E+ from D- on 7/25/2024 due to a decline in the volatility index, total return index and valuation index.
D
Sell
7/10/2024Upgraded
Zeo ScientifiX, Inc. (ZEOX) was upgraded to D- from E+ on 7/10/2024 due to an increase in the total return index, volatility index and valuation index.
Zeo ScientifiX, Inc. (ZEOX) was upgraded to D- from E+ on 7/10/2024 due to an increase in the total return index, volatility index and valuation index.
E
Sell
3/7/2024Downgrade
Zeo ScientifiX, Inc. (ZEOX) was downgraded to E+ from D- on 3/7/2024 due to a decline in the volatility index and valuation index.
Zeo ScientifiX, Inc. (ZEOX) was downgraded to E+ from D- on 3/7/2024 due to a decline in the volatility index and valuation index.
D
Sell
2/21/2024Upgraded
Organicell Regenerative Medicine, Inc. (OCEL) was upgraded to D- from E+ on 2/21/2024 due to a major increase in the solvency index, growth index and volatility index. Operating cash flow increased 147.5% from -$464.2 to $220.5, the quick ratio increased from 0.2 to 0.45, and earnings per share increased from -$0.2277 to -$0.1551.
Organicell Regenerative Medicine, Inc. (OCEL) was upgraded to D- from E+ on 2/21/2024 due to a major increase in the solvency index, growth index and volatility index. Operating cash flow increased 147.5% from -$464.2 to $220.5, the quick ratio increased from 0.2 to 0.45, and earnings per share increased from -$0.2277 to -$0.1551.
E
Sell
12/28/2023Downgrade
Organicell Regenerative Medicine, Inc. (OCEL) was downgraded to E+ from D- on 12/28/2023 due to a decline in the total return index and volatility index.
Organicell Regenerative Medicine, Inc. (OCEL) was downgraded to E+ from D- on 12/28/2023 due to a decline in the total return index and volatility index.
D
Sell
12/13/2023Upgraded
Organicell Regenerative Medicine, Inc. (OCELD) was upgraded to D- from E+ on 12/13/2023 due to an increase in the valuation index.
Organicell Regenerative Medicine, Inc. (OCELD) was upgraded to D- from E+ on 12/13/2023 due to an increase in the valuation index.
E
Sell
11/28/2023Downgrade
Organicell Regenerative Medicine, Inc. (OCELD) was downgraded to E+ from D- on 11/28/2023 due to a major decline in the solvency index, total return index and valuation index. Debt to equity increased from -3.61 to -0.62, and the quick ratio declined from 0.39 to 0.2.
Organicell Regenerative Medicine, Inc. (OCELD) was downgraded to E+ from D- on 11/28/2023 due to a major decline in the solvency index, total return index and valuation index. Debt to equity increased from -3.61 to -0.62, and the quick ratio declined from 0.39 to 0.2.
D
Sell
9/12/2023Upgraded
Organicell Regenerative Medicine, Inc. (OCEL) was upgraded to D- from E+ on 9/12/2023 due to a noticeable increase in the total return index, valuation index and volatility index.
Organicell Regenerative Medicine, Inc. (OCEL) was upgraded to D- from E+ on 9/12/2023 due to a noticeable increase in the total return index, valuation index and volatility index.
E
Sell
3/14/2023Downgrade
Organicell Regenerative Medicine, Inc. (OCEL) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index and volatility index.
Organicell Regenerative Medicine, Inc. (OCEL) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index and volatility index.
D
Sell
2/16/2023Upgraded
Organicell Regenerative Medicine, Inc. (OCEL) was upgraded to D from D- on 2/16/2023 due to a significant increase in the solvency index and growth index. The quick ratio increased from 0.03 to 0.97, and earnings per share increased from -$0.0025 to -$0.0023.
Organicell Regenerative Medicine, Inc. (OCEL) was upgraded to D from D- on 2/16/2023 due to a significant increase in the solvency index and growth index. The quick ratio increased from 0.03 to 0.97, and earnings per share increased from -$0.0025 to -$0.0023.
D
Sell
2/8/2023Downgrade
Organicell Regenerative Medicine, Inc. (OCEL) was downgraded to D- from D on 2/8/2023 due to a decline in the growth index and solvency index. Operating cash flow declined 1,127.39% from -$63.9 to -$784.3, EBIT declined 119.53% from -$1.26M to -$2.76M, and earnings per share declined from -$0.0014 to -$0.0025.
Organicell Regenerative Medicine, Inc. (OCEL) was downgraded to D- from D on 2/8/2023 due to a decline in the growth index and solvency index. Operating cash flow declined 1,127.39% from -$63.9 to -$784.3, EBIT declined 119.53% from -$1.26M to -$2.76M, and earnings per share declined from -$0.0014 to -$0.0025.
D
Sell
5/16/2022Upgraded
Organicell Regenerative Medicine, Inc. (OCEL) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
Organicell Regenerative Medicine, Inc. (OCEL) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
Organicell Regenerative Medicine, Inc. (OCEL) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index and volatility index.
Organicell Regenerative Medicine, Inc. (OCEL) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index and volatility index.
D
Sell
5/4/2022Upgraded
Zeo ScientifiX, Inc. (ZEOX) was upgraded to D from E+ on 05/04/2022.
Zeo ScientifiX, Inc. (ZEOX) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/3/2022Downgrade
Organicell Regenerative Medicine, Inc. (OCEL) was downgraded to E+ from D on 5/3/2022 due to a decline in the volatility index and total return index.
Organicell Regenerative Medicine, Inc. (OCEL) was downgraded to E+ from D on 5/3/2022 due to a decline in the volatility index and total return index.
D
Sell
5/2/2022Upgraded
Organicell Regenerative Medicine, Inc. (OCEL) was upgraded to D from E+ on 5/2/2022 due to an increase in the volatility index.
Organicell Regenerative Medicine, Inc. (OCEL) was upgraded to D from E+ on 5/2/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Downgrade
Organicell Regenerative Medicine, Inc. (OCEL) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and total return index.
Organicell Regenerative Medicine, Inc. (OCEL) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and total return index.
D
Sell
4/21/2022Upgraded
Organicell Regenerative Medicine, Inc. (OCEL) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index.
Organicell Regenerative Medicine, Inc. (OCEL) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index.
E
Sell
4/20/2022Downgrade
Organicell Regenerative Medicine, Inc. (OCEL) was downgraded to E+ from D on 4/20/2022 due to a large decline in the total return index, volatility index and solvency index.
Organicell Regenerative Medicine, Inc. (OCEL) was downgraded to E+ from D on 4/20/2022 due to a large decline in the total return index, volatility index and solvency index.
D
Sell
11/23/2021Upgraded
Zeo ScientifiX, Inc. (ZEOX) was upgraded to D from D- on 11/23/2021.
Zeo ScientifiX, Inc. (ZEOX) was upgraded to D from D- on 11/23/2021.
D
Sell
11/8/2021Downgrade
Organicell Regenerative Medicine, Inc. (BPSR) was downgraded to D- from D on 11/8/2021 due to a significant decline in the total return index and volatility index.
Organicell Regenerative Medicine, Inc. (BPSR) was downgraded to D- from D on 11/8/2021 due to a significant decline in the total return index and volatility index.
D
Sell
10/16/2020Downgrade
Organicell Regenerative Medicine, Inc. (BPSR) was downgraded to D from C- on 10/16/2020 due to a significant decline in the efficiency index, solvency index and valuation index. Net income declined 106.14% from -$350.3 to -$722.1, and total capital declined 3.95% from -$870.3 to -$904.7.
Organicell Regenerative Medicine, Inc. (BPSR) was downgraded to D from C- on 10/16/2020 due to a significant decline in the efficiency index, solvency index and valuation index. Net income declined 106.14% from -$350.3 to -$722.1, and total capital declined 3.95% from -$870.3 to -$904.7.
C
Hold
10/30/2018Upgraded
Biotech Products Services and Research, Inc. (BPSR) was upgraded to C- from D+ on 10/30/2018 due to an increase in the total return index and volatility index.
Biotech Products Services and Research, Inc. (BPSR) was upgraded to C- from D+ on 10/30/2018 due to an increase in the total return index and volatility index.
D
Sell
8/15/2018Downgrade
Biotech Products Services and Research, Inc. (BPSR) was downgraded to D+ from C- on 8/15/2018 due to a noticeable decline in the total return index.
Biotech Products Services and Research, Inc. (BPSR) was downgraded to D+ from C- on 8/15/2018 due to a noticeable decline in the total return index.
C
Hold
7/20/2018Upgraded
Biotech Products Services and Research, Inc. (BPSR) was upgraded to C- from D+ on 7/20/2018 due to a major increase in the total return index and volatility index.
Biotech Products Services and Research, Inc. (BPSR) was upgraded to C- from D+ on 7/20/2018 due to a major increase in the total return index and volatility index.
D
Sell
6/15/2018Upgraded
Biotech Products Services and Research, Inc. (BPSR) was upgraded to D+ from D on 6/15/2018 due to a noticeable increase in the total return index, growth index and volatility index. Operating cash flow increased 82.26% from -$752.4 to -$133.5, earnings per share increased from -$0.0271 to -$0.0079, and EBIT increased 65.36% from -$2.6M to -$901.4.
Biotech Products Services and Research, Inc. (BPSR) was upgraded to D+ from D on 6/15/2018 due to a noticeable increase in the total return index, growth index and volatility index. Operating cash flow increased 82.26% from -$752.4 to -$133.5, earnings per share increased from -$0.0271 to -$0.0079, and EBIT increased 65.36% from -$2.6M to -$901.4.
D
Sell
7/13/2017Upgraded
Biotech Products Services and Research, Inc. (BPSR) was upgraded to D from D- on 7/13/2017 due to a significant increase in the efficiency index and valuation index.
Biotech Products Services and Research, Inc. (BPSR) was upgraded to D from D- on 7/13/2017 due to a significant increase in the efficiency index and valuation index.
D
Sell
7/7/2017Downgrade
Biotech Products Services and Research, Inc. (BPSR) was downgraded to D- from D on 7/7/2017 due to a significant decline in the efficiency index, growth index and solvency index. Total revenue declined 241% from $26.1 to -$36.8, earnings per share declined from -$0.0022 to -$0.0041, and total capital declined 84.77% from -$369.7 to -$683.1.
Biotech Products Services and Research, Inc. (BPSR) was downgraded to D- from D on 7/7/2017 due to a significant decline in the efficiency index, growth index and solvency index. Total revenue declined 241% from $26.1 to -$36.8, earnings per share declined from -$0.0022 to -$0.0041, and total capital declined 84.77% from -$369.7 to -$683.1.
D
Sell
2/27/2017Upgraded
Biotech Products Services and Research, Inc. (BPSR) was upgraded to D from E+ on 2/27/2017 due to a significant increase in the efficiency index, growth index and volatility index. Operating cash flow increased 48.94% from -$240.9 to -$123, earnings per share increased from -$0.003 to -$0.0022, and EBIT increased 26.5% from -$295.5 to -$217.2.
Biotech Products Services and Research, Inc. (BPSR) was upgraded to D from E+ on 2/27/2017 due to a significant increase in the efficiency index, growth index and volatility index. Operating cash flow increased 48.94% from -$240.9 to -$123, earnings per share increased from -$0.003 to -$0.0022, and EBIT increased 26.5% from -$295.5 to -$217.2.
E
Sell
8/19/2016None
Zeo ScientifiX, Inc. (ZEOX) was downgraded to E+ from U on 08/19/2016.
Zeo ScientifiX, Inc. (ZEOX) was downgraded to E+ from U on 08/19/2016.
OTC PK
03/14/2025 10:02AM Eastern
Quotes delayed
